内蒙古医科大学学报
內矇古醫科大學學報
내몽고의과대학학보
Journal of Inner Mongolia Medical University
2014年
3期
222-225
,共4页
边红霞%徐海峰%郭媛%白海燕
邊紅霞%徐海峰%郭媛%白海燕
변홍하%서해봉%곽원%백해연
视网膜中央静脉阻塞%持续性黄斑水肿%光学相干断层扫描%曲安奈德%雷珠单抗
視網膜中央靜脈阻塞%持續性黃斑水腫%光學相榦斷層掃描%麯安奈德%雷珠單抗
시망막중앙정맥조새%지속성황반수종%광학상간단층소묘%곡안내덕%뢰주단항
central retinal vein occlusion%persistent macular edema%triamcinolone acetonide
目的:鉴于视网膜中央静脉阻塞central retinal vein occlusion( CRVO);所致持续性黄斑水肿persistent macular edema(ME);治疗有很多争议,探讨更有效的治疗办法。方法:玻璃体腔注射曲安奈德(TA)31例、注射抗血管内皮生长因子单克隆抗体(Ranibizumab)30例,和两组中注药加激光21例,通过测量视力、眼压,中央视网膜厚度等方面来探讨玻璃体腔注射Ranibizumab、TA和注药+激光光凝治疗效果,并应用统计学方法进行分析对比。结果:注射Ranibizumab组和TA组:最佳矫正视力在注药前后对比,两组均有显著统计学差异。中央视网膜厚度在注药前后对比,两组亦均有统计学差异。结论:玻璃体腔注射TA与Ranibizumab在治疗CRVO继发黄斑水肿时,均在短期内能明显降低水肿的视网膜和改善视力, Ranibizumab反复注射的次数要比TA多一些;TA比Ranibizumab副作用多,安全性差。激光和注药相比并不能够改善视力,但对减轻水肿和防止新生血管性青光眼有作用,故在必须时要慎重选择。
目的:鑒于視網膜中央靜脈阻塞central retinal vein occlusion( CRVO);所緻持續性黃斑水腫persistent macular edema(ME);治療有很多爭議,探討更有效的治療辦法。方法:玻璃體腔註射麯安奈德(TA)31例、註射抗血管內皮生長因子單剋隆抗體(Ranibizumab)30例,和兩組中註藥加激光21例,通過測量視力、眼壓,中央視網膜厚度等方麵來探討玻璃體腔註射Ranibizumab、TA和註藥+激光光凝治療效果,併應用統計學方法進行分析對比。結果:註射Ranibizumab組和TA組:最佳矯正視力在註藥前後對比,兩組均有顯著統計學差異。中央視網膜厚度在註藥前後對比,兩組亦均有統計學差異。結論:玻璃體腔註射TA與Ranibizumab在治療CRVO繼髮黃斑水腫時,均在短期內能明顯降低水腫的視網膜和改善視力, Ranibizumab反複註射的次數要比TA多一些;TA比Ranibizumab副作用多,安全性差。激光和註藥相比併不能夠改善視力,但對減輕水腫和防止新生血管性青光眼有作用,故在必鬚時要慎重選擇。
목적:감우시망막중앙정맥조새central retinal vein occlusion( CRVO);소치지속성황반수종persistent macular edema(ME);치료유흔다쟁의,탐토경유효적치료판법。방법:파리체강주사곡안내덕(TA)31례、주사항혈관내피생장인자단극륭항체(Ranibizumab)30례,화량조중주약가격광21례,통과측량시력、안압,중앙시망막후도등방면래탐토파리체강주사Ranibizumab、TA화주약+격광광응치료효과,병응용통계학방법진행분석대비。결과:주사Ranibizumab조화TA조:최가교정시력재주약전후대비,량조균유현저통계학차이。중앙시망막후도재주약전후대비,량조역균유통계학차이。결론:파리체강주사TA여Ranibizumab재치료CRVO계발황반수종시,균재단기내능명현강저수종적시망막화개선시력, Ranibizumab반복주사적차수요비TA다일사;TA비Ranibizumab부작용다,안전성차。격광화주약상비병불능구개선시력,단대감경수종화방지신생혈관성청광안유작용,고재필수시요신중선택。
Objective:Central retinal vein occlusion ( CRVO ) induced persistent macular edema ( ME) by more effective measures,as there is a lot of controversy treatment. Methods:injection of tri-amcinolone acetonide ( TA ) was in 31 cases, vascular endothelial growth factor monoclonal antibody (Ranibizumab)was in 30 cases,and 21 cases was drug injection plus laser in two groups,the visual acuity,intraocular pressure,central retinal thickness(CRT) were measured to evaluate the treatment effect of intravitreal injection of Ranibizumab,TA and injection +laser photocoagulation,and statistical methods were used for analysis and comparison. Results:The best-corrected visual acuity( BCVA) are significant difference compared with before injections. The central retinal thickness are also. Conclusion:Intravitreal injections of TA and Ranibizumab in two groups are effective in the treatment of CRVO secondary to CME. The number of repeated injection of Ranibizumab is more than that of TA;TA has some more side effect,poor safety,Laser and injection then cannot improve eyesight,but they can alleviate edema and neovascular glaucoma, so when necessary, they can be chosen, but not excessive treatment.